ArticleBMC cancer2025
Vismodegib treatment in locally advanced basal cell carcinoma limited to the facial region: a single-center experience.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness of the Temporal Flap in Reconstruction After Advanced External Ear Tumor Resection: A Case Report.Clinics and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBasal cell carcinoma (BCC) is the most common non-melanoma skin cancer. Treatment typically begins with surgical intervention. However, in cases of locally advanced and metastatic BCC (laBCC and mBCC), Hedgehog signaling pathway inhibitors such as sonidegib and vismodegib are used. MATERIALS AND
methodsThis retrospective study included 28 adult patients with laBCC who were treated with 150 mg daily oral vismodegib at Mehmet Akif Ersoy State Hospital between 2018 and 2023. Patients were monitored until disease progression, intolerable side effects, or treatment discontinuation. Treatment efficacy was evaluated using objective response rate (ORR) and disease control rate (DCR). Safety was assessed based on adverse events (AEs) reported in accordance with the CTCAE v. 5.0 classification. Statistical analyses, including overall survival (OS) and progression-free survival (PFS), were performed and analyzed using SPSS version 25.
resultsThe overall ORR was 89.3%, with 39.3% of patients achieving complete response (CR). The median PFS was 15.1 months, and the median OS was 37.5 months. Female gender and prior surgical interventions were identified as independent prognostic factors for PFS, while ECOG-PS score and the duration of vismodegib exposure were significant predictors of OS. AEs were reported in 78.6% of patients, with dysgeusia and muscle spasms being the most prevalent. Grade 3 or 4 toxicity occurred in 14.5% of patients, and 13% (n = 3) discontinued treatment due to AEs. Patients receiving treatment for ≥ 12 months experienced a higher incidence of AEs (92.9%) compared to those treated for < 12 months (64.3%).
conclusionVismodegib demonstrated high efficacy in treating patients with laBCC, with a significant proportion achieving CR. However, long-term treatment was associated with an increased incidence of AEs, highlighting the need for careful monitoring of safety in prolonged therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.